METTL14は,m6Aに依存するPD-1の損失によって抗腫瘍免疫を強化する

Chang Huang¹, Xiaodong Wang², Yinmin Gu³

¹Guizhou University, Zunyi, China.

Cancer research

|August 27, 2025

まとめ

PDCD1遺伝子のN6-メチラデノシン (m6A) 変異はT細胞機能に影響する. この発見は,このm6A調節軸をターゲットにすることで,がん免疫療法を強化するための新しい戦略を明らかにしています.

科学分野:

免疫学
エピジェネティクス
分子生物学

背景:

N6-メチラデノシン (m6A) は,遺伝子発現と免疫反応に影響を与える重要な表表表記学的変化である.
プログラム細胞死-1 (PD-1) は,T細胞活動を調節する重要な免疫チェックポイント受容体であり,がん免疫療法の標的である.

研究の目的:

PDCD1 (PD-1) 遺伝子発現の調節におけるm6A変異の役割とそのT細胞機能への影響を調査する.
癌の免疫療法を改善するためにm6A-PDCD1軸を標的とする可能性を調査する.

主な方法:

T細胞におけるPDCD1 mRNAのm6A変異の分析
PDCD1 mRNAの不安定化におけるMETTL14,YTHDF1/2/3の役割を調査する.
マウスモデルにおけるCD8+T細胞活性化と腫瘍増殖に対するMETTL14欠乏の影響を評価する.
METTL14とPDCD1のレベルを臨床がんデータと免疫療法応答と関連付けています.
METTL3-METTL14複合分解剤 (WD6305) と抗PD-1治療の組み合わせをインビボで評価する.

主要な成果:

PDCD1遺伝子発現は,T細胞のm6A変異によって制御される.
METTL14は,YTHDF1/ 2/ 3経由でPDCD1のm6A依存の不安定化を促進し,PDCD1のダウンレギュレーションにつながります.
METTL14欠乏症はCD8+ T細胞の活性化を阻害し,PD-1濃度の上昇により腫瘍の成長を促進する.
臨床データは,METTL14とPDCD1レベルとの間の負の関連を示し,PD-1免疫療法に対する抵抗と相関しています.
WD6305と抗PD-1を併用した治療は,マウスの腫瘍増殖を抑制した.

結論:

PDCD1のm6A変異は,T細胞機能と腫瘍免疫に影響を与える新しい免疫調節メカニズムを表しています.
m6A- PDCD1軸をターゲットに,特にMETTL14調節または組み合わせた治療法により,抗PD-1がん免疫療法の有効性を高める有望な戦略を提供します.

さらに関連する動画

10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K

09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

関連する概念動画

02:23

Abnormal Proliferation

4.6K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

4.6K

01:27

Tumor Immunotherapy

659

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

659

03:03

mTOR Signaling and Cancer Progression

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

3.9K

02:17

The Tumor Microenvironment

6.8K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...